Bracco Diagnostics Inc. and Lantheus Medical Imaging, Inc


in
Bracco Diagnostics Inc. and Lantheus Medical Imaging, Inc. announced that the companies have entered into an agreement for Lantheus to co-promote Bracco's CardioGen-82(R) (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for the evaluation of coronary artery disease (CAD). This co-promotion agreement is a strategic fit for Lantheus and demonstrates company continued commitment to advancing the field of diagnostic imaging through company unparalleled distribution network, superior customer service and tremendous sales and medical affairs field organization.